Nov 30, 2022
LivaNova to Present Scientific Data at American Epilepsy Society 2022 Annual Meeting
LONDON --(BUSINESS WIRE)--Nov. 30, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced its participation in the American Epilepsy Society (AES) 2022 Annual Meeting, taking place December 2-6 in Nashville, Tennessee .
Nov 17, 2022
LivaNova Receives 510(k) Clearance for ECMO from FDA for LifeSPARC, the Next-generation Advanced Circulatory Support System
Platform simplifies life support, making life-saving technology more accessible to hospitals and critically ill patients LONDON --(BUSINESS WIRE)--Nov. 17, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced it received 510(k) clearance
Nov 08, 2022
LivaNova to Present at the Stifel, Wolfe and Piper Sandler Healthcare Conferences
LONDON --(BUSINESS WIRE)--Nov. 8, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced its Chief Executive Officer Damien McDonald will present a general business update during fireside chats at three healthcare conferences in New York this
Nov 02, 2022
LivaNova Reports Third-Quarter 2022 Results
LONDON --(BUSINESS WIRE)--Nov. 2, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended September 30, 2022 . Financial Summary and Highlights 1 Revenue of $252.6 million for the quarter decreased 0.2 percent on a
Sep 21, 2022
LivaNova to Announce Third-Quarter 2022 Results
LONDON --(BUSINESS WIRE)--Sep. 21, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its third-quarter 2022 results on Wednesday, November 2, 2022 , at 12 p.m.   London time ( 8 a.m. EDT ).
Sep 15, 2022
LivaNova Board Appoints Brooke Story as a New Director
  LONDON --(BUSINESS WIRE)--Sep. 15, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the LivaNova Board of Directors appointed Brooke Story to the Board, effective September 15, 2022 . In addition, Story will be a member of the
Aug 03, 2022
LivaNova Reports Second-Quarter 2022 Results
LONDON --(BUSINESS WIRE)--Aug. 3, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended June 30, 2022 . Financial Summary and Highlights 1 Revenue of $254.2 million for the quarter, decreased 3.9 percent on a
Jun 22, 2022
LivaNova to Announce Second-Quarter 2022 Results
LONDON --(BUSINESS WIRE)--Jun. 22, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its second-quarter 2022 results on Wednesday, August 3, 2022 at 1 p.m.   London time ( 8 a.m. EDT ).
Jun 14, 2022
LivaNova Elects Peter Wilver to Board of Directors
LONDON --(BUSINESS WIRE)--Jun. 14, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced Peter Wilver has been elected to the Board of Directors, effective immediately. His election was part of the LivaNova 2022 Annual General Meeting of
May 25, 2022
LivaNova to Present at the Goldman Sachs Global Healthcare Conference
LONDON --(BUSINESS WIRE)--May 25, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced Damien McDonald , Chief Executive Officer, will present in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference in Rancho Palos
May 04, 2022
LivaNova Reports First-Quarter 2022 Results
LONDON --(BUSINESS WIRE)--May 4, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter ended March 31, 2022 . Financial Summary and Highlights 1 Worldwide sales were $240.2 million , a decrease of 3.0 percent on a
Apr 08, 2022
LivaNova Initiates Targeted Commercial Launch of the Essenz Patient Monitor for Cardiopulmonary Bypass Procedures
Intuitive monitor featuring patient-tailored approach is now in clinical use in select centers in U.S. and Europe LONDON --(BUSINESS WIRE)--Apr. 8, 2022-- LivaNova PLC (NASDAQ: LIVN), a market-leading medical technology and innovation company, today announced receipt of regulatory approvals and the
Mar 24, 2022
LivaNova to Announce First-Quarter 2022 Results
LONDON --(BUSINESS WIRE)--Mar. 24, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its first-quarter 2022 results on Wednesday, May 4, 2022 at 1 p.m.   London time ( 8 a.m. EDT ).
Mar 14, 2022
LivaNova Announces 250th Unipolar Depression Patient Implanted in RECOVER Clinical Study
LONDON --(BUSINESS WIRE)--Mar. 14, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the 250th unipolar depression patient has been implanted in the RECOVER clinical study , “A P r ospective, Multi-c e nter, Randomized C ontrolled
Feb 24, 2022
LivaNova Announces First Patient Implanted in OSPREY Clinical Study for Patients Coping with Obstructive Sleep Apnea
Study to evaluate effectiveness of hypoglossal nerve stimulation LONDON --(BUSINESS WIRE)--Feb. 24, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the first patient implanted in the investigational device exemption (IDE) clinical
Feb 23, 2022
LivaNova Reports Fourth-Quarter and Full-Year 2021 Results
LONDON --(BUSINESS WIRE)--Feb. 23, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today reported results for the quarter and full year ended December 31, 2021 . For the fourth quarter of 2021, worldwide sales from continuing operations were $270.1
Jan 12, 2022
LivaNova to Announce Fourth-Quarter and Full-Year 2021 Results
LONDON --(BUSINESS WIRE)--Jan. 12, 2022-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, will host a conference call to discuss its fourth-quarter and full-year 2021 results on Wednesday, February 23, 2022 at 1 p.m.   London time ( 8 a.m. Eastern Time ).